Dubai – Sharikat Mubasher: Tenvie Therapeutics launched today with a mission to transform neurological disease treatment.
The company, backed by $200 million in funding, has drawn significant support from Mubadala Capital, along with ARCH Venture Partners and F-Prime Capital, according to a recent press release.
Combining assets acquired from Denali Therapeutics Inc. with an expert R&D team, Tenvie aims to develop groundbreaking small molecule therapies.
Tony Estrada, Ph.D., President and Chief Scientific Officer of Tenvie commented: “Tenvie was founded to fundamentally alter the treatment paradigm for neurological diseases and profoundly impact the lives of patients, their families, and caregivers”. The company focuses on resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function, with advanced programs like an NLRP3 inhibitor and an allosteric SARM1 inhibitor already in the IND-enabling stage.
Alaa Halawa, Mubadala Capital’s Head of Healthcare and a Tenvie Board Director, highlighted the importance of the company’s mission, saying: “Tenvie’s approach demonstrates a commitment to addressing unmet needs in neurology”. Mubadala Capital’s investment underscores its strategy to back innovative ventures addressing critical healthcare challenges.
Tenvie’s leadership team includes accomplished figures in CNS drug development and business operations, positioning the company to lead advancements in neurology. With Mubadala Capital’s support, Tenvie is set to make significant strides in delivering next-generation therapies for patients worldwide.
